Provided by Tiger Fintech (Singapore) Pte. Ltd.

Praxis Precision Medicines, Inc.

35.34
+1.554.59%
Pre-market: 35.630.2897+0.82%08:49 EDT
Volume:558.77K
Turnover:19.73M
Market Cap:712.57M
PE:-3.46
High:36.70
Open:33.48
Low:32.78
Close:33.79
Loading ...

Praxis Precision Medicines: Idmc Recommended Essential3 Study Be Stopped for Futility, Due to Results Being Unlikely to Meet Primary Efficacy Endpoint

THOMSON REUTERS
·
28 Feb

Praxis Precision Medicines: to Continue Essential3 Program Studies to Completion, With Topline Results Expected in Q3

THOMSON REUTERS
·
28 Feb

Praxis Precision Medicines: Decision About Whether Data Supports Submission of Nda to Be Made After Analyzing Final Results for Study 1 & Study 2

THOMSON REUTERS
·
28 Feb

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

GlobeNewswire
·
28 Feb

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
27 Feb

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
25 Feb

Steven Cohen's Strategic Acquisition in Praxis Precision Medicines Inc

GuruFocus
·
15 Feb

Praxis Precision Med Initiated at Buy by Deutsche Bank

Dow Jones
·
12 Feb

Praxis Precision initiated with a Buy at Deutsche Bank

TIPRANKS
·
11 Feb

Praxis Precision Med Price Target Maintained With a $150.00/Share by Needham

Dow Jones
·
10 Feb

Buy Recommendation for Ulixacaltamide Stock Amid Phase 3 Study Scenarios

TIPRANKS
·
10 Feb

BRIEF-Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
05 Feb

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Piper Sandler Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

TIPRANKS
·
31 Jan

Praxis Precision Med Is Maintained at Buy by Truist Securities

Dow Jones
·
22 Jan

TD Cowen Sticks to Their Buy Rating for Praxis Precision Medicines (PRAX)

TIPRANKS
·
21 Jan

Truist Securities Adjusts Price Target on Praxis Precision Medicines to $175 From $150, Keeps Buy Rating

MT Newswires Live
·
21 Jan

Truist Financial Releases a Buy Rating on Praxis Precision Medicines (PRAX)

TIPRANKS
·
21 Jan

U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth

Reuters
·
21 Jan

Praxis Precision Medicines Inc : Truist Securities Raises Target Price to $175 From $150

THOMSON REUTERS
·
21 Jan